Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Device to treat resistant hypertension lowers blood pressure by 33 points

A device designed to treat people with resistant hypertension helped lower blood pressure by 33 points, a substantial drop that would otherwise require patients to take an additional three or four drugs, on top of this subgroup's usual regimen of up to five drugs, to control their difficult-to-treat condition.

6 Apr 2011

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Abbott today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClip® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.

5 Apr 2011

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

Milliman Care Guidelines today presented its Doyle Award for Innovation and Leadership in Healthcare to ADVANTAGE Health Solutions, Inc.(SM) and to Sound Physicians. The awards were presented in ceremonies here at the Milliman Care Guidelines Client Forum.

5 Apr 2011

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Two new retrospective subanalyses of the RE-LY trial, involving Pradaxa capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin occurred irrespective of CHA2DS2-VASc risk score and the type of non-valvular atrial fibrillation.

5 Apr 2011

Adherence to guideline-related therapies can reduce heart failure patients' mortality rate

A UCLA-led study has found that adherence to national guideline-recommended therapies for heart failure in an outpatient practice setting significantly lowered the mortality rate of heart failure patients.

5 Apr 2011

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

NorthShore University HealthSystem interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial, that were concurrently published in The New England Journal of Medicine.

5 Apr 2011

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

The Harvard Clinical Research Institute and Saint Luke's Mid America Heart and Vascular Institute today announced that Matthew R. Reynolds, M.D., Director of the Economics and Quality of Life Research Center at HCRI, presented results of a cost-effectiveness analysis of transcatheter aortic valve replacement versus standard therapy for severe aortic stenosis, as part of the opening plenary session on April 3 at the American College of Cardiology 60th Annual Scientific Session & Expo.

5 Apr 2011

Researchers to develop future body sensor network

Modern man is surrounded by a multitude of sensors. Today's sensors are simple and made for specific purposes, like measuring temperature, balance, build-up of smoke, or tyre pressure. The common trait of the sensors is that they are all embedded in a closed system.

5 Apr 2011

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana.

5 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the final results from the PROTECT II study, presented by William O'Neill, M.D., Dean of University of Miami and Principal Investigator of PROTECT II, at the American College of Cardiology's 60th Annual Scientific Session and i2 Summit 2011 in New Orleans.

4 Apr 2011

Men who consume digoxin have 24% reduced risk of prostate cancer

Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.

4 Apr 2011

Scientists identify digoxin as possible therapy for prostate cancer

Scientists have identified digoxin as a possible therapy for prostate cancer, using a combination of laboratory science and epidemiology that is unprecedented in its cooperative nature.

4 Apr 2011

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

This week, AIDS Healthcare Foundation, the largest global AIDS organization, launched a public tribute to Hollywood legend Elizabeth Taylor with a number of billboards around Los Angeles commemorating her contribution to the AIDS fight.

2 Apr 2011

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

A novel cardiac biomarker, ST2, will be highlighted in three presentations at the American College of Cardiology in New Orleans this week.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Nile's post-acute development program for cenderitide, which has the goal of reducing cardiovascular mortality and cardiovascular re-hospitalization in the post-acute period in patients with acute decompensated heart failure.

31 Mar 2011

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced that it has obtained exclusive rights from New York University for intellectual property covering methods of use in modulating microRNA-33a and microRNA-33b for metabolic diseases such as atherosclerosis and metabolic syndrome.

31 Mar 2011

Abbott launches MitraClip system to treat MR in Australia

Abbott today announced the launch of the company's catheter-based MitraClip system for the treatment of mitral regurgitation in Australia. The MitraClip device, which has received Therapeutic Goods Administration approval, offers a new treatment option for patients suffering from MR, a debilitating heart valve condition.

31 Mar 2011

Drugs' cost deters patients from taking heart medicine

For more than 5 million Americans with heart failure, a critical step to better health is taking the medications they're prescribed. But many patients fail to do so, putting themselves at greater risk of hospitalization and even death. To date, studies have not fully answered why patients fall short when it comes to taking heart medicine. In a study appearing in the April issue of Mayo Clinic Proceedings, Mayo Clinic researchers found the drugs' cost is one of the biggest deterrents.

30 Mar 2011

Heart Failure News and Research

Further Reading

Device to treat resistant hypertension lowers blood pressure by 33 points

MR patients treated with Abbott MitraClip system demonstrate clinical benefits of initial treatment at two years

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

RE-LY trial results suggest Pradaxa capsule reduces risk of stroke in AF patients

Adherence to guideline-related therapies can reduce heart failure patients' mortality rate

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

HCRI, MAHVI present transcatheter aortic valve data in severe stenosis at ACC meeting

Researchers to develop future body sensor network

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abiomed presents Impella PROTECT II study final results in PCI at ACC and i2 Summit

Men who consume digoxin have 24% reduced risk of prostate cancer

Scientists identify digoxin as possible therapy for prostate cancer

AHF launches public tribute to Hollywood legend with billboards around Los Angeles

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

FDA grants Nile Fast Track designation for cenderitide post-acute development program

Regulus obtains exclusive rights from NYU for miR-33a, 33b to treat metabolic diseases

Abbott launches MitraClip system to treat MR in Australia

Drugs' cost deters patients from taking heart medicine

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News